UBS Group’s Emmaus Life Sciences, Inc. Common Stock EMMA Stock Holding History

UBS Group’s Portfolio EMMA Stock Details EMMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-191	Closed	-$1K	–	8531
2019 Q2	$1K	Sell	191 -380	-67%	-$2.82K	﹤0.01%	7803
2019 Q1	$5K	Sell	571 -930	-62%	-$8.3K	﹤0.01%	7225
2018 Q4	$7K	Buy	+1,501	New	+$12.1K	﹤0.01%	7452
2018 Q3	–	Sell	-726	Closed	-$8K	–	8479
2018 Q2	$8K	Buy	726 +565	+351%	+$7.46K	﹤0.01%	7302
2018 Q1	$1K	Buy	161 +158	+5,267%	+$2.56K	﹤0.01%	7717
2017 Q4	$0	Buy	+3	New	+$66	﹤0.01%	8275

Other funds holding EMMA

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

UBS Group's EMMA Position: Q3 2019 in Review

UBS Group sold out of Emmaus Life Sciences, Inc. Common Stock (EMMA) in Q3 2019, closing a stake of 191 shares — an estimated $1K sold.

UBS Group first reported a position in EMMA in Q4 2017 and held it in 6 quarters. The position peaked at $8K in Q2 2018. 1 fund tracked by Wall St. Rank holds EMMA as of Q3 2019.

UBS Group reported no remaining Emmaus Life Sciences, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
UBS Group sold 191 Emmaus Life Sciences, Inc. Common Stock shares in Q3 2019, an estimated $1K.
UBS Group first reported a position in Emmaus Life Sciences, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
UBS Group's Emmaus Life Sciences, Inc. Common Stock position peaked at $8K in Q2 2018.
1 fund tracked by Wall St. Rank held Emmaus Life Sciences, Inc. Common Stock as of Q3 2019.

Based on UBS Group's 13F filing for Q3 2019, filed 14 Nov 2019.